Introduction Alpha-1-adrenergic receptors (a1-ARs) are G-protein coupled receptors (GPCRs) with three highly homologous subtypes (a1A, a1B, and a1D). Of these three subtypes, only the a1A and a1B are expressed in the heart. Multiple pre-clinical models of heart injury demonstrate cardioprotective roles for the a1A. Non-selective a1-AR activation promotes glycolysis in the heart, but the functional a1-AR subtype and broader metabolic effects have not been studied. Objectives Given the high metabolic demands of the heart and previous evidence indicating benefit from a1A activation, we chose to investigate the effects of a1A activation on the cardiac metabolome in vivo. Methods Mice were treated for 1 week with a low, subpressor dose of A61603, a highly selective and potent a1A agonist. Cardiac tissue and serum were analyzed using a non-targeted metabolomics approach.
Introduction
Adrenergic receptors (ARs) are G-protein coupled receptors (GPCRs) that are activated endogenously by catecholamines and play critical roles in regulating cardiac function. The b1-AR is the most abundant AR in the heart and chronic activation of b1-ARs by catecholamines contributes to the pathobiology of heart failure. a1-ARs are less abundant, but play adaptive and protective roles in the heart, including induction of physiological cardiac hypertrophy, enhanced cardiac contractility, and protection against multiple forms of cardiac injury .
Pharmacologic approaches have been used for decades to elucidate downstream effects of non-selective a1-AR activation. The endogenous catecholamines norepinephrine and epinephrine activate a1-ARs as well as b-ARs, whereas the synthetic drug phenylephrine is a non-selective a1-AR agonist used widely in experimental settings. Studies using these agents have identified important roles for a1-ARs in regulation of glucose metabolism in skeletal muscle (Hutchinson and Bengtsson 2006) , liver (Thomas et al. 1985) , pancreas (Skoglund et al. 1987) , and adipocytes (Fitzpatrick et al. 2001) . Non-selective a1-AR activation in the heart increases glucose metabolism (Clark et al. 1982; Egert et al. 1999 ) and decreases fatty acid oxidation (Barger et al. 2000) . This metabolic substrate switch from fatty acid to glucose is a critical component of the heart's adaptation to stress (Pascual and Coleman 2016; Griffin et al. 2016) . Despite the central role of catecholamines in cardiac biology, very little is known about their global metabolic effects in the heart. One previous study investigated the effects of b-AR stimulation on the rat cardiac metabolome (Liu et al. 2013 ), but the broad metabolic effects of a1-AR stimulation have not been investigated.
There are three highly homologous subtypes of a1-ARs: a1A, a1B, and a1D, with variable tissue expression throughout the body. The a1A and a1B are expressed in the rodent and human heart, whereas the a1D is found in the coronary vasculature and mediates vasoconstriction (Turnbull et al. 2003; Jensen et al. 2009 ). Transgenic mouse models and pharmacologic approaches have begun to delineate distinct roles for the cardiac a1-AR subtypes, indicating that the a1A is cytoprotective in vitro and cardioprotective in vivo . Transgenic mice overexpressing the a1A in cardiomyocytes demonstrate enhanced contractility and functional recovery after ischemic challenge and pressure overload (Du et al. 2006; Woodcock 2007; Zhao et al. 2015) .
Recent studies have expanded these observations using the potent and highly selective a1A agonist, A61603 (N-[5-(4,5-dihydro-1H-imidazol-2yl)-2-hydroxy-5,6,7,8-tetrahydro naphthalen-1-yl] methanesulfonamide hydrobromide) (Knepper et al. 1995) in multiple preclinical studies (Snabaitis et al. 2000; Luo et al. 2007; Cowley et al. 2015; ) . A61603 protects against cardiomyocyte death due to multiple cytotoxic exposures in vitro (Huang et al. 2007 ), prevents doxorubicin-induced cardiotoxicity in vivo (Dash et al. 2011) , and restores right ventricular contractility in a mouse model of right heart failure (Cowley et al. 2015) . Importantly, these beneficial effects were achieved using a dose of A61603 that did not increase blood pressure, suggesting that vascular a1-ARs were not activated, and reinforcing the possibility that selective a1A-AR activation might represent a novel approach to treating heart muscle disease (Jensen et al. 2011) . It is unknown whether metabolic alterations contribute to these beneficial effects.
In the present study, mice were treated with A61603 then heart tissue and serum were analyzed using a nontargeted metabolomics approach to discover whether broad metabolic adaptations may underlie the cardioprotective effects of activating the a1A-AR in vivo.
2 Materials and methods 2.1 Animals, experimental design, drug delivery, and harvest
Mice were 12-week old C57Bl6J males. All mice underwent implantation of subcutaneous osmotic minipump (Alzet) that delivered A61603 10 ng/kg/days to eight mice and vehicle (100 lM vitamin C, 0.9 % NaCl) to eight mice for 1 week. Mice were fed the usual animal care diet per the San Francisco VA Animal Care facility. Mice were sacrificed under deep isoflurane anesthesia, blood was collected by cardiac puncture, clotted, and 100-200 lL serum was snap frozen in liquid nitrogen. The heart was dissected, the atria and great vessels were excised, and the ventricles were allowed to beat in cold PBS to clear blood. Excess liquid was blotted then the heart was snap-frozen in liquid nitrogen and shipped to Metabolon (Durham, NC).
Ultrahigh performance liquid chromatographytandem mass spectroscopy (UPLC-MS/MS)
All methods utilized a Waters ACQUITY ultra-performance liquid chromatography (UPLC) and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer operated at 35,000 mass resolution. Samples were processed as previously described (Lawton et al. 2008; Evans et al. 2009 ), sample extract reconstituted in solvents containing a series of standards at fixed concentrations to ensure injection and chromatographic consistency. One aliquot was analyzed using acidic positive ion conditions, chromatographically optimized for more hydrophilic compounds. The extract was gradient eluted from a C18 column (Waters UPLC BEH C18-2.1 9 100 mm, 1.7 lm) using water and methanol, containing 0.05 % perfluoropentanoic acid (PFPA) and 0.1 % formic acid (FA). Another aliquot was also analyzed using acidic positive ion conditions, however it was chromatographically optimized for more hydrophobic compounds. In this method, the extract was gradient eluted from the same C18 column using methanol, acetonitrile, water, 0.05 % PFPA and 0.01 % FA and was operated at an overall higher organic content. Another aliquot was analyzed using basic negative ion optimized conditions using a separate dedicated C18 column. The basic extracts were gradient eluted from the column using methanol and water, however with 6.5 mM Ammonium Bicarbonate at pH 8. The fourth aliquot was analyzed via negative ionization following elution from a HILIC column (Waters UPLC BEH amide 2.1 9 150 mm, 1.7 lm) using a gradient consisting of water and acetonitrile with 10 mM ammonium formate, pH 10.8. The MS analysis alternated between MS and data-dependent MS n scans using dynamic exclusion. The scan range varied slightly between methods but covered 70-1000 m/z. Raw data were extracted, peak-identified by comparison to library entries of purified standards or recurrent unknown entities based on authenticated standards that contain the retention time/index (RI), mass to charge ratio (m/z), and chromatographic data (including MS/MS spectral data). Biochemical identifications are based on retention index within a narrow RI window of the proposed identification, accurate mass match to the library ±10 ppm, and the MS/MS forward and reverse scores between the experimental data and authentic standards. The MS/MS scores are based on a comparison of the ions present in the experimental spectrum to the ions present in the library spectrum. The QC and curation processes were designed to ensure accurate and consistent identification of true chemical entities, and to remove those representing system artifacts, misassignments, and background noise. Peaks were quantified using area-under-the-curve. For studies spanning multiple days, a data normalization step was performed to correct variation resulting from instrument inter-day tuning differences. All data used in this analysis has been archived in the UCSD Metabolomics Workbench (http://www.metabolomicsworkbench.org/), accession # ST000451 and ST000452.
Metabolomic statistical analyses
Metaboanalyst (v3.0) run on the statistical package R (v2.14.0) used metabolite peak areas (as representative of concentration) (Xia et al. 2009; Xia et al. 2015) . These data were first normalized to a pooled average sample from the relevant vehicle-treated group, and scaled using Pareto scaling feature. To detect systemic metabolic signature of A61603 treatment, a Pairwise One-Way Analysis of Variance (ANOVA) and Fisher LSD post hoc test across the tissues (heart, serum) and experimental groups (vehicle treated, A61603-treated) were performed using Metaboanalyst v3.0. ANOVA significant metabolites (FDR \ 0.05) were matched to metabolomics pathways using the Pathway Analysis and enrichment analysis features in Metaboanalyst 3.0. Only metabolites identified and detected in all groups were included in the one-way ANOVA. Up to three missing values in each group were imputed. If four or more values of each metabolite were missing in a given group, the entire metabolite was removed from the analysis. Only metabolites significantly altered between tissue-matched control and A61603 treatment groups were included. All data from this study are available in Supplemental Table 1 . Heat maps were generated using the GENE-E software (http://www.broad institute.org/cancer/software/GENE-E/index.html) and Microsoft Excel 2016. All data are shown as mean ± -SEM, unless otherwise indicated.
Results

Heart tissue
We compared heart tissue from mice treated for 7 days with the selective a1A-AR agonist, A61603, or vehicle. We used a very low A61603 dose, 10 ng/kg/day, that has no detectable effect on blood pressure, heart rate, heart size (Supplemental Fig. 1 ), or heart function, but does increase phosphorylation of cardiac ERK, a canonical a1A signaling partner. (Manuscript in preparation, Montgomery MD et al. 2016 ) Of note, this dose of A61603 previously was shown to protect mice against doxorubicin-induced cardiotoxicity (Dash et al. 2011 ) and preserve right ventricular contractile function in the setting of pulmonary hypertension (Cowley et al. 2015) . All comparisons used a one-way ANOVA to identify significantly altered metabolites. Of the 503 total metabolites identified in heart, 381 were adequate for the one-way ANOVA (Supplemental Figs. 2 and 3) , and 30 were ANOVA-significant with a false discovery rate (FDR) \0.05 (Fig. 1a) . Metaboanalyst recognized 23 of these 30 metabolites and applied pathway analysis to identify biosynthesis of A B C Fig. 1 Analysis of non-targeted metabolomics of hearts from vehicle-treated and A61603-treated mice. a Summary heat map of pairwise One-way ANOVA significant metabolites, determined by Fisher-LSD post hoc test results. Fisher LSD post hoc comparisons were made between A61603-treated and vehicle-treated heart groups (N = 8/group). b Pathway enrichment analysis for A61603-treated heart group compared to vehicle-treated heart group, determined by ANOVA significant metabolites in the heart. A-C indicates top pathways identified c. Enrichment analysis of cardiac A61603-mediated alterations compared to pathway metabolite sets unsaturated fatty acids as the most affected pathway (Fig. 1b , p = 1.29E -11 , FDR = 1.06E -9 ). Metaboanalyst enrichment analysis for pathways identified alpha linoleic acid and linoleic acid metabolism, ammonia recycling, and urea cycle with the lowest p values, enriched three to tenfold (Fig. 1c) . Enrichment analysis for location identified the peroxisome with the lowest p values, enriched 1.5-to 2.0-fold expected (data not shown).
Of the seven metabolites not recognized by Metaboanalyst for pathway analysis using multiple synonymous chemical names (i.e. N-palmitoyl taurine*, 1-(1-enylstearoyl)-GPE, palmitoylethanolamide*, N-stearoyltaurine*, oleoyl ethanolamide*, 1-palmitoyl GPG, 10-nonadecanoic acid, 15-methylpalmitate), four are involved in the endocannabinoid (EC) Pathway. The EC system consists of cannabinoid receptors and their endogenous neuromodulatory lipid ligands that collectively play longrecognized roles in the neurological and immunological systems (Vasileiou et al. 2013) and recently have been identified in the heart (O'Sullivan 2015). We found a roughly 50 % decrease in the abundance of the biologically active EC metabolites oleoyl ethanolamide, palmitoyl ethanolamide, N-stearoyltaurine, and N-palmitoyltaurine after treatment with A61603 (Fig. 2) .
Review of specific metabolites within these pathways revealed a 25 % decrease in cardiac arachidonic acid, an omega (x)-6 polyunsaturated fatty acid (PUFA) (Figs. 2,  3b) . Similarly, we found decreases of *25-45 % in eight metabolites involved in the synthesis of x3 (Fig. 3a) and x6 fatty acids (Fig. 3b) . Biosynthesis of PUFAs, including arachidonic acid, occurs through multiple desaturation and elongation steps (Fig. 3b) , each controlled by distinct enzymes (Guillou et al. 2010) . Our findings suggest that activation of the a1A broadly reduces x3 and x6 fatty acid synthesis, possibly through regulation of one or more of these desaturates and elongases.
There was no clear signal that a1A activation affected glucose metabolism, though pyruvate levels were consistently and significantly decreased in hearts of A61603-treated mice (Fig. 1a) . Collectively, these findings suggest that A61603-treatment significantly affects the biosynthesis of biologically active PUFAs and EC receptor ligands.
Serum
Of the 543 total metabolites identified in serum, 381 were adequate for one-way ANOVA (Supplemental Fig. 4 and 5), and 34 of them were ANOVA significant with an FDR \ 0.05 (Fig. 4a) . Pathway analysis of these 34 metabolites identified pyrimidine metabolism as the most likely affected pathway ( Fig. 4b, c ; p = 0.026, FDR = 1). The pyrimidine salvage pathway (Fig. 5) recovers core pyrimidine components which are recycled for use as nucleic acids or for recovery of nitrogen to the general nitrogen metabolism (Zrenner et al. 2009 ). Further analysis of metabolites in the pyrimidine salvage pathway revealed that A61603 treatment is associated with significant decreases in serum levels of deoxycytidine, deoxyuridine, and ureidopropionate (Fig. 5) . All three of these metabolites are intermediates in b-alanine synthesis, but A61603 treatment did not affect abundance of b-alanine in either serum or heart.
Of note, treatment with A61603 had no effect on serum glucose, cholesterol, or creatinine levels-three commonly used markers of cardiovascular risk in the clinical setting. Collectively, these findings suggest relatively minimal systemic effects from the administration of an a1A agonist.
Heart and serum
We next determined if there were A61603-altered metabolites in the serum that might reflect A61603-altered metabolites in the heart and might serve as circulating markers of cardiac response to A61603. No such metabolites were found using our initial stringent cut-off of FDR \0.05. When we decreased the stringency to FDR \0.10 and identified A61603-induced metabolites compared to the vehicle controls (Supplemental Fig. 8A ), only 5-hydroxylysine, a hydroxylated lysine derivative found in certain collagens, overlapped in both compartments (Supplemental Fig. 8A, top row) .
We next compared these groups using one-way ANOVA (Supplemental Fig. 8B ). Though there was a statistically significant change in 5-hydroxylysine in A61603-treated heart compared to its vehicle control (p \ 0.02) (Supplemental Fig. 8B) , there was no significant change in A61603-treated serum (Supplemental Fig. 8B ). As such, the metabolite subset recognized in the current study did not identify a reliable serum metabolite marker for the cardiac effects of A61603.
Discussion
In this study, we used non-targeted metabolomics analysis to identify previously unrecognized links between pharmacological a1A-AR activation and biosynthesis of PUFAs and ECs in the heart. These findings expand our limited understanding of the adrenergic regulation of the cardiac metabolome and generate novel hypotheses regarding the activity of cardiac a1A-ARs. In particular, PUFAs and ECs both play central roles in inflammation, suggesting that regulation of inflammation may contribute to the demonstrated cardioprotective effects of the selective a1A agonist, A61603.
We discovered that systemic treatment with A61603 broadly reduced the cardiac content of x3, x6, and x9 PUFAs without affecting serum PUFA levels. PUFAs play critical and complex roles in the heart, acting act as both biosynthetic intermediates and signaling molecules (van Bilsen and Planavila 2014) . Observational studies have linked higher serum x3-PUFA levels and dietary PUFA intake with lower mortality due to cardiovascular disease (Mozaffarian et al. 2013 ). However, the biological relevance of PUFA abundance in cardiac tissue is uncertain and rodent models have demonstrated that dietary PUFA content is not correlated with heart content (Cleland et al. 2005) . Previous reports indicate that treatment with PUFAs leads to a decrease in a1-AR mediated contractility in cultured cardiomyocytes (Reithmann et al. 1996; Delerive et al. 1999) , but the role of cardiac a1-ARs in regulating PUFA biosynthesis has not been explored.
We found decreases in ostensibly beneficial x3 PUFAs such as docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA) (Kang and Leaf 1996) , as well as more cardiotoxic PUFAs such as the x9 PUFA, erucic acid (BeareRogers et al. 1974; Imamura et al. 2013) . Arachidonic acid (AA), among the most extensively studied of PUFAs, was decreased to 0.74-fold relative abundance in the hearts of mice treated with A61603. Previous studies have reached variable conclusions about the function of AA in the heart, in part because AA metabolites play conflicting rolessome beneficial (Gross et al. 2005 ) and some maladaptive (Alsaad et al. 2013) . AA is released from membrane A B Fig. 3 Functional annotation of N-3 and N-6 unsaturated fatty acid biosynthesis including intermediates altered in heart tissue by in vivo A61603. a1A-mediated alterations in a N-3 poly-unsaturated fatty acids (PUFAs) and b N-6 poly-unsaturated fatty acids (PUFAs) in the heart, determined by one-way ANOVA (p \ 0.05). D (delta) references the specific double bonds present in fatty acids. Data represent mean ± SEM. (N = 8/group). *p \ 0.05 Fig. 4 Analysis of non-targeted metabolomics of serum from vehicle-treated and A61603-treated mice. a Summary heat map of pairwise one-way ANOVA significant metabolites, determined by Fisher-LSD post hoc test results (significance defined as FDR \ 0.05). Fisher LSD post hoc comparisons were made between A61603-treated and vehicle-treated serum groups (N = 8/group).
Only significantly altered metabolites are shown. Significance was defined as FDR \ 0.05. b Pathway enrichment analysis for A61603-treated serum group compared to vehicle-treated serum group. A-C indicates top pathways identified. c Enrichment analysis of A61603-mediated alterations in serum compared to pathway metabolite sets phospholipids by phospholipases. a1-AR stimulation activates phospholipase C (Steinberg et al. 1989 ) and phospholipase D (Parmentier et al. 2002; Gosau et al. 2002) , which cleave phospholipids to diacyl glycerol (DAG) and phosphatidic acid respectively. These lipid products are then enzymatically converted to AA. In our study, A61603 treatment increased total DAG content by 24 % (p \ 0.05). The observed decrease in AA content could potentially result from regulation of DAG lipase-the enzyme that converts DAG to AA-or through an increase in conversion of AA to downstream metabolites.
PUFAs have not been studied widely in injured heart tissue. PUFA abundance in the heart is not affected by activation of the angiotensin I receptor (Mervaala et al. 2010) , and treatment with the b-AR agonist isoproterenol increases AA 3.4-fold and the x6 PUFA linolelaidic acid 2.5-fold (Liu et al. 2013) . Chronic activation of both the angiotensin I receptor and the b-AR lead to maladaptive cardiac hypertrophy and heart failure. Consistent with these findings, AA and DHA increase in failing human heart tissue as well as hypertrophied and failing rat hearts (Le et al. 2014) . In contrast, sustained a1A activation leads to a decrease in PUFA levels and cardioprotection, though the mechanistic connection between these findings is uncertain. Collectively, these studies illustrate the complexity of ascribing inherent benefit or harm to tissue PUFA levels.
Our results also indicate that pharmacological activation of the a1A-AR leads to decreased levels of ECs in the heart. ECs are metabolites in the AA biosynthetic pathway, formed by activation of fatty acid amid hydrolase (Cravatt et al. 1996) . ECs participate in the regulation of cellular metabolism and inflammation through activation of CB1, CB2, and TRPV1 channels. The effects of ECs in the heart are either beneficial (Duerr et al. 2014) or maladaptive (Batkai et al. 2004; Al Kury et al. 2014) , depending on context and selective receptor activation (Hiley 2009 ).
Cardioprotective mechanisms induced by EC modulation include enhanced Na ? /Ca 2? exchange current (Li et al. 2013) , activation of HSP72, PKA, PLC, PKC, eNOS, iNOS, and ERK1/2 (Gonzalez et al. 2011; Li et al. 2013; Cappellano et al. 2013) , and regulation of myosin heavy chain isoform switching (Duerr et al. 2014) . Interestingly, a1-AR activation regulates each of these processes in the heart as well, suggesting that the EC system may participate broadly in the mechanisms underlying a1-mediated cardioprotection. Of particular significance to our current study, ECs have been shown to decrease responsiveness to AR agonist stimulation in the vasculature (Marichal-Cancino et al. 2013; Szekeres et al. 2015) , to mediate a1-induced glutamate neurotransmission in the central nervous system (Haj-Dahmane and Shen 2014), and to regulate peripheral norepinephrine release (Lowin and Straub 2015) . However, our study is the first to show an effect of a1-AR activation on EC biosynthesis. Given the complex functions of both PUFAs and the EC system in the heart, it is unclear how our findings might help to explain the cardioprotective effects of a1 À ARs. However, one reasonable hypothesis is that a1A activation regulates inflammation, insofar as many of the metabolites that were reduced in A61603-treated hearts are involved in inflammatory pathways. ECs are well-recognized mediators of systemic inflammatory diseases such as rheumatoid arthritis (Lowin and Straub 2015) , and also regulate inflammation in the heart (Moris et al. 2015) . PUFAs regulate T lymphocyte function (Nicolaou et al. 2014 ) and modify inflammatory diseases (Calder 2006 ) and AA and its metabolites provide critical positive and negative regulation of systemic and cardiac inflammation (Mozaffarian and Wu 2011) . Inflammation, defined here as the recruitment of immune cells or the activation in the myocardium of pathways classically associated with immune cell activation, is central to the biology of acute myocardial injury (Frangogiannis et al. 2002) and to the pathophysiology of chronic heart failure (Yndestad et al. 2007 ); a1A activation is protective in both settings. The role of inflammation in the heart is complex, however, and inflammatory mediators released from both circulating cells or any of the resident cell cardiac types play both adaptive and maladaptive roles. Regulated activation of inflammatory pathways after acute myocardial injury can facilitate tissue repair, but chronic hyperactivation of these same pathways may contribute to adverse cardiac remodeling and heart failure (Dick and Epelman 2016) .
The role of a1-ARs in regulating cardiac inflammation has not been explored to any significant extent. Transgenic mice overexpressing a constitutively active a1A have increased IL-6 expression in the heart, but no evidence of increased cardiac inflammation (Perez et al. 2009 ). These mice are protected against ischemia-reperfusion injury, a condition that typically is worsened by inflammation. One other study found that non-selective a1-AR activation suppresses lipopolysaccharide-induced cardiomyocyte TNF-a expression and improves cardiac dysfunction during endotoxemia through ERK activation and NF-jB suppression (Yu et al. 2014) . a1-ARs are found on monocytes and macrophages, and their activation appears to alter production of inflammatory mediators (Grisanti et al. 2011) . The current study cannot distinguish direct metabolic effects of A61603 on cardiomyocyte a1As from secondary effects on the heart due to activation of a1As expressed on other tissue, including immune cells. Unfortunately, there are no extant transgenic mice with immune cell-specific alterations of a1A expression, hence we lack the tools to address this question directly. Our analysis of the serum of mice treated with A61603 revealed no clear evidence of systemic inflammatory modulation, though reduction in pyrimidine salvage intermediates (Fig. 5) , would favor a reduction in inflammatory cell function (Rudolph et al. 1990; Breedveld and Dayer 2000) .
Conclusion
In this study, we treated mice with the selective a1A-adrenergic receptor agonist, A61603, at a dose previously shown to be cardioprotective in multiple models of heart injury. We found that A61603 induced significant changes in the cardiac metabolome, most notably in the biosynthesis of polyunstaturated fatty acids and endocannabinoids. These novel findings suggest previously unrecognized roles for a1A-adrenergic receptors in the heart, and may expand our understanding of the mechanisms underlying the cardioprotective effects of a1A-adrenergic receptor activation.
